MASTHEAD
About the Semaglutide Telehealth Digest
A data-forward reading of the semaglutide trial record — what it is, and what it deliberately is not.
What this site is
Semaglutide Telehealth Digest reads the semaglutide trial record data-first: it takes the peer-reviewed literature, sets the head-to-head figures against tirzepatide side by side, and reconciles each number to the study that produced it. Despite the name, no telehealth happens here — no clinic, no clinician, no diagnosis, no dose advice, and no way to obtain the drug; the ledger only reads and cites. Semaglutide is an approved medicine with a large evidence base, and the job is to keep that ledger accurately.
The approach is data-forward: we lead with the measured figure — the weight percentage, the hazard ratio, the confidence interval — and trace it to the study that produced it. The organizing lens of this particular digest is the head-to-head comparison against tirzepatide, because that 2025 question (SURMOUNT-5) is the one readers most often arrive asking, and because reading the two drugs side by side clarifies what each one's evidence actually shows.
What "telehealth" means here — and what it does not
The word "telehealth" in this site's name is editorial framing — a position this publisher takes relative to the literature, reading the record with an eye to availability and access questions. It is not a description of services. This site is not a telehealth provider. It offers no consultations, no prescriptions, no intake forms, and no path to obtain semaglutide. There is no clinician, pharmacist, or clinical team behind it, and none is implied.
We make this explicit because the distinction matters: a digest that reads the evidence is a fundamentally different thing from a service that dispenses care. We are firmly the former.
How we handle the evidence
Three rules govern every page. First, every quantitative claim is cited to a primary source — a trial, a review, or a drug monograph — listed in full on the references page. Second, we use only generic compound names; we never use brand names. Third, we describe doses only as they appear in published trials and approved labeling, in the third person, and never as a recommendation for any reader.
We also keep a clearly labeled line between evidence and anecdote. The effects page reports what people in patient communities describe, marked explicitly as anecdotal and unverified, and keeps it separate from the cited clinical findings. Semaglutide is an approved medicine with a large, real evidence base; our job is to summarize that base accurately, not to sell it, defend it, or prescribe it.